Search

Your search keyword '"Desai, Jayesh"' showing total 863 results
Start Over Author "Desai, Jayesh"
863 results on '"Desai, Jayesh"'

202. Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapy

Author

Snow, Hayden, primary, Mitchell, Catherine, additional, Hendry, Shona, additional, McKinley, Madeleine, additional, Byrne, David, additional, Ngan, Sam, additional, Chander, Sarat, additional, Chu, Julie, additional, Desai, Jayesh, additional, Bae, Susie, additional, Henderson, Michael, additional, Choong, Peter, additional, and Gyorki, David, additional

Published
2020
Full Text
View/download PDF

203. CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research

Author

Kee, Damien, primary, Parker, Clare, additional, Bae, Susie, additional, Tucker, Katherine M., additional, Harrison, Michelle, additional, Tohidi-Esfahani, Ibrahim, additional, Black, Marita, additional, Delahunty, Rachel, additional, Ananda, Sumitra, additional, Friedlander, Michael, additional, Cunliffe, Heather E., additional, Gibbs, Peter, additional, Desai, Jayesh, additional, Trotman, Judith, additional, and Scott, Clare L., additional

Published
2020
Full Text
View/download PDF

204. Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

Author

Bendell, Johanna C., primary, Bedard, Philippe, additional, Bang, Yung-Jue, additional, LoRusso, Patricia, additional, Hodi, Stephen, additional, Gordon, Michael, additional, D'Angelo, Sandra, additional, Desai, Jayesh, additional, Garralda, Elena, additional, Italiano, Antoine, additional, Ahn, Myung-Ju, additional, Cervantes, Andres, additional, Wainberg, Zev, additional, Calvo, Emiliano, additional, Gil-Martin, Marta, additional, Martinez-Garcia, Maria, additional, Bahleda, Rastilav, additional, Cassier, Philippe, additional, Delord, Jean-Pierre, additional, Prawira, Amy, additional, Melero, Ignacio, additional, Emens, Leisha, additional, Romano, Emanuela, additional, Miller, Karen, additional, Hsieh, Robert W., additional, Xue, Cloris, additional, Morrissey, Kari, additional, Twomey, Patrick, additional, Gash, Kelly, additional, Patil, Namrata S., additional, Grogan, Jane, additional, Meng, Raymond, additional, Cho, Byoung, additional, and Kim, Tae Won, additional

Published
2020
Full Text
View/download PDF

207. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Author

Desai, Jayesh, primary, Gan, Hui, additional, Barrow, Catherine, additional, Jameson, Michael, additional, Atkinson, Victoria, additional, Haydon, Andrew, additional, Millward, Michael, additional, Begbie, Stephen, additional, Brown, Michael, additional, Markman, Ben, additional, Patterson, William, additional, Hill, Andrew, additional, Horvath, Lisa, additional, Nagrial, Adnan, additional, Richardson, Gary, additional, Jackson, Christopher, additional, Friedlander, Michael, additional, Parente, Phillip, additional, Tran, Ben, additional, Wang, Lai, additional, Chen, Yunxin, additional, Tang, Zhiyu, additional, Huang, Wendy, additional, Wu, John, additional, Zeng, Dewan, additional, Luo, Lusong, additional, and Solomon, Benjamin, additional

Published
2020
Full Text
View/download PDF

208. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Author

Desai, Jayesh, primary, Deva, Sanjeev, additional, Lee, Jong Seok, additional, Lin, Chia-Chi, additional, Yen, Chia-Jui, additional, Chao, Yee, additional, Keam, Bhumsuk, additional, Jameson, Michael, additional, Hou, Ming-Mo, additional, Kang, Yoon-Koo, additional, Markman, Ben, additional, Lu, Chang-Hsien, additional, Rau, Kun-Ming, additional, Lee, Kyung-Hun, additional, Horvath, Lisa, additional, Friedlander, Michael, additional, Hill, Andrew, additional, Sandhu, Shahneen, additional, Barlow, Paula, additional, Wu, Chi-Yuan, additional, Zhang, Yun, additional, Liang, Liang, additional, Wu, John, additional, Paton, Virginia, additional, and Millward, Michael, additional

Published
2020
Full Text
View/download PDF

209. Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts).

Author

Smith, Kortnye Maureen, primary, O Haire, Sophie, additional, Khuong-Quang, Dong Anh, additional, Markman, Ben, additional, Gan, Hui Kong, additional, Ekert, Paul G, additional, O'Byrne, Kenneth John, additional, Millward, Michael, additional, Solomon, Benjamin J., additional, Tran, Ben, additional, Scott, Clare L., additional, Kee, Damien, additional, McArthur, Grant A., additional, Fellowes, Andrew, additional, Weerasuriya, Rona, additional, Lynch, Elly, additional, Martyn, Melissa, additional, Gaff, Clara, additional, Fox, Stephen B., additional, and Desai, Jayesh, additional

Published
2020
Full Text
View/download PDF

210. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

Author

Kopetz, Scott, primary, Grothey, Axel, additional, Van Cutsem, Eric, additional, Yaeger, Rona, additional, Wasan, Harpreet Singh, additional, Yoshino, Takayuki, additional, Desai, Jayesh, additional, Ciardiello, Fortunato, additional, Loupakis, Fotios, additional, Hong, Yong Sang, additional, Steeghs, Neeltje, additional, Guren, Tormod Kyrre, additional, Arkenau, Hendrik-Tobias, additional, Garcia-Alfonso, Pilar, additional, Gollerkeri, Ashwin, additional, Maharry, Kati, additional, Christy-Bittel, Janna, additional, and Tabernero, Josep, additional

Published
2020
Full Text
View/download PDF

211. Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC).

Author

Desai, Jayesh, primary, Wang, Jie, additional, Zhou, Qing, additional, Zhao, Jun, additional, Deva, Sanjeev, additional, Tan, Wei, additional, Ma, Xiaopeng, additional, Zhang, Yun, additional, Shen, Zhirong, additional, Wu, Xikun, additional, Leaw, Shiangjiin, additional, Wu, Yanjie, additional, and Wu, Yi-Long, additional

Published
2020
Full Text
View/download PDF

213. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).

Author

Kopetz, Scott, primary, Grothey, Axel, additional, Van Cutsem, Eric, additional, Yaeger, Rona, additional, Wasan, Harpreet Singh, additional, Yoshino, Takayuki, additional, Desai, Jayesh, additional, Ciardiello, Fortunato, additional, Loupakis, Fotios, additional, Hong, Yong Sang, additional, Steeghs, Neeltje, additional, Guren, Tormod Kyrre, additional, Arkenau, Hendrik-Tobias, additional, Garcia-Alfonso, Pilar, additional, Gollerkeri, Ashwin, additional, Maharry, Kati, additional, Christy-Bittel, Janna, additional, Keir, Christopher Hunt, additional, Pickard, Michael D, additional, and Tabernero, Josep, additional

Published
2020
Full Text
View/download PDF

214. CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.

Author

Fakih, Marwan, primary, Desai, Jayesh, additional, Kuboki, Yasutoshi, additional, Strickler, John H., additional, Price, Timothy Jay, additional, Durm, Greg Andrew, additional, Falchook, Gerald Steven, additional, Denlinger, Crystal S., additional, Krauss, John C., additional, Shapiro, Geoffrey, additional, Kim, Tae Won, additional, Park, Keunchil, additional, Coveler, Andrew L., additional, Munster, Pamela N., additional, Li, Bob T., additional, Kim, June, additional, Henary, Haby Adel, additional, Ngarmchamnanrith, Gataree, additional, and Hong, David S., additional

Published
2020
Full Text
View/download PDF

216. NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment.

Author

Kee, Damien, primary, Kondrashova, Olga, additional, Ananda, Sumitra, additional, Brown, Michael Paul, additional, Cohen, Paul Andrew, additional, Dean, Andrew, additional, Desai, Jayesh, additional, Fellowes, Andrew, additional, Fox, Stephen B., additional, Hadley, Alison, additional, Lindsay, Dianne, additional, Mileshkin, Linda R., additional, O'Byrne, Kenneth John, additional, Prall, Owen W.J., additional, Scott, Hamish, additional, Thomas, David Morgan, additional, Vines, Richard, additional, Waddell, Nic, additional, Papenfuss, Anthony, additional, and Scott, Clare L., additional

Published
2020
Full Text
View/download PDF

217. Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia

Author

Delahunty, Rachel, primary, Lee, Margaret, additional, Wong, Hui‐Li, additional, Johns, Julie, additional, Mckendrick, Joseph, additional, Lee, Belinda, additional, Kosmider, Suzanne, additional, Cooray, Prasad, additional, Ananda, Sumitra, additional, Desai, Jayesh, additional, Tran, Ben, additional, Tie, Jeanne, additional, Gibbs, Peter, additional, and Wong, Rachel, additional

Published
2020
Full Text
View/download PDF

218. A Malignant Neoplasm From the Jejunum With aMALAT1-GLI1Fusion and 26-Year Survival History

Author

Prall, Owen William John, primary, McEvoy, Christopher Robert Edward, additional, Byrne, David John, additional, Iravani, Amir, additional, Browning, Judy, additional, Choong, David Yew-Huong, additional, Yellapu, Bhargavi, additional, O’Haire, Sophie, additional, Smith, Kortnye, additional, Luen, Stephen James, additional, Mitchell, Paul Leslie Ross, additional, Desai, Jayesh, additional, Fox, Stephen Bernard, additional, Fellowes, Andrew, additional, and Xu, Huiling, additional

Published
2020
Full Text
View/download PDF

219. CD8 + tumor‐infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival

Author

Millen, Rosemary, primary, Hendry, Shona, additional, Narasimhan, Vignesh, additional, Abbott, Rebecca, additional, Croxford, Matthew, additional, Gibbs, Peter, additional, Tie, Jeanne, additional, Wong, Hui‐Li, additional, Jones, Ian, additional, Kosmider, Suzanne, additional, Byrne, David, additional, Zalcberg, John, additional, Fox, Stephen, additional, Desai, Jayesh, additional, Visvanathan, Kumar, additional, Ramsay, Robert G, additional, and Tran, Ben, additional

Published
2020
Full Text
View/download PDF

230. iPREDICT: Incorporating complex profiling of patients to enrol onto molecularly directed cancer therapeutics. Preliminary results of the adult and paediatric cohorts

Author

Smith, Kortnye Maureen, O Haire, Sophie, Khuong-quang, Dong Anh, Markman, Ben, Gan, Hui K., Ekert, Paul G, O'Byrne, Ken, Milward, Michael, Solomon, Ben J., Tran, Ben, Scott, Clare, Mcarthur, Grant A., Kee, Damien, Fellowes, Andrew, Huiling, Xu, Martyn, Melissa, Lynch, Elly, Lorgelly, Paula K., Gaff, Clara, Fox, Stephen, Desai, Jayesh, Smith, Kortnye Maureen, O Haire, Sophie, Khuong-quang, Dong Anh, Markman, Ben, Gan, Hui K., Ekert, Paul G, O'Byrne, Ken, Milward, Michael, Solomon, Ben J., Tran, Ben, Scott, Clare, Mcarthur, Grant A., Kee, Damien, Fellowes, Andrew, Huiling, Xu, Martyn, Melissa, Lynch, Elly, Lorgelly, Paula K., Gaff, Clara, Fox, Stephen, and Desai, Jayesh

Abstract

Background: Tumour molecular profiling is an important component of precision oncology. The genomic rearrangements identified in tumours now contribute important information to facilitate accurate diagnosis, prognosis and increasingly can guide therapeutic decisions. iPREDICT (iPR) is a national precision medicine study, offering targeted next generation sequencing (NGS) to adult and paediatric patients with high-risk solid tumours with the aim of identifying actionable variants to guide treatment decisions. Aims: This prospective study was designed to assess patient perception, feasibility and clinical impact of a personalised medicine approach utilising NGS for patients with advanced cancer. Methods: iPREDICT was conducted across seven hospitals utilising NGS (PMCC Comprehensive Cancer Panel; 391 genes). A molecular tumour board was established to evaluate results and treatment recommendations. A detailed evaluation of the testing process, result delivery and patient and trial staff perception was conducted though validated and study-specific surveys, discrete choice experiments and semi-structured interviews. Results: Between April 2017 and September 2018, 315 patients with advanced cancer were enrolled across seven sites and underwent tumour and matched germline NGS. 84% (265) had successful tests. Of patients with successful tests, 208 potentially actionable findings were detected in 144 (55%). 41 (15%) went on to receive a change in treatment; six6 (2%) avoided therapy thought not to be beneficial, nine (3%) received new access to funded therapy, 17 (6%) enrolled on targeted trials and nine (3%) patients commenced off-label therapy. Germline mutations were detected in 46 (17%). A formal evaluation of patient choice and perception of the testing process have provided important insights into health care implementation. Conclusions: Our findings confirm feasibility of molecular profiling in high-risk solid tumours in the Austra

Published
2019

231. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

Author

Daiichi-Sankyo, Tap, William D., Gelderblom, Hans, Palmerini, Emanuela, Desai, Jayesh, Bauer, Sebastian, Blay, Jean-Yves, Alcindor, Thierry, Ganjoo, Kristen, Martín-Broto, Javier, Ryan, Christopher W., Thomas, David M., Peterfy, Charles, Healey, John H., van de Sande, Michiel, Gelhorn, Heather L., Shuster, Dale E., Wang, Qiang, Yver, Antoine, Hsu, Henry H., Lin, Paul S., Tong-Starksen, Sandra, Stacchiotti, Silvia, Wagner, Andrew J., Daiichi-Sankyo, Tap, William D., Gelderblom, Hans, Palmerini, Emanuela, Desai, Jayesh, Bauer, Sebastian, Blay, Jean-Yves, Alcindor, Thierry, Ganjoo, Kristen, Martín-Broto, Javier, Ryan, Christopher W., Thomas, David M., Peterfy, Charles, Healey, John H., van de Sande, Michiel, Gelhorn, Heather L., Shuster, Dale E., Wang, Qiang, Yver, Antoine, Hsu, Henry H., Lin, Paul S., Tong-Starksen, Sandra, Stacchiotti, Silvia, and Wagner, Andrew J.

Abstract

[Background] Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. We aimed to evaluate pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT to provide them with a viable systemic treatment option, especially in cases that are not amenable to surgical resection., [Methods] This phase 3 randomised trial had two parts. Part one was a double-blind study in which patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assigned via an integrated web response system (1:1) to the pexidartinib or placebo group. Individuals in the pexidartinib group received a loading dose of 1000 mg pexidartinib per day orally (400 mg morning; 600 mg evening) for the first 2 weeks, followed by 800 mg per day (400 mg twice a day) for 22 weeks. Part two was an open-label study of pexidartinib for all patients. The primary endpoint, assessed in all intention-to-treat patients, was overall response at week 25, and was centrally reviewed by RECIST, version 1.1. Safety was analysed in all patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov, number NCT02371369., [Findings] Between May 11, 2015, and Sept 30, 2016, of 174 patients assessed for eligibility, 120 patients were randomly assigned to, and received, pexidartinib (n=61) or placebo (n=59). There were 11 dropouts in the placebo group and nine in the pexidartinib group. Emergence of mixed or cholestatic hepatotoxicity caused the data monitoring committee to stop enrolment six patients short of target. The proportion of patients who achieved overall response was higher for pexidartinib than placebo at week 25 by RECIST (24 [39%] of 61 vs none of 59; absolute difference 39% [95% CI 27–53]; p<0·0001). Serious adverse events occurred in eight (13%) of 61 patients in the pexidartinib group and one (2%) of 59 patients in the placebo group. Hair colour changes (67%), fatigue (54%), aspartate aminotransferase increase (39%), nausea (38%), alanine aminotransferase increase (28%), and dysgeusia (25%) were the most frequent pexidartinib-associated adverse events. Three patients given pexidartinib had aminotransferase elevations three or more times the upper limit of normal with total bilirubin and alkaline phosphatase two or more times the upper limit of normal indicative of mixed or cholestatic hepatotoxicity, one lasting 7 months and confirmed by biopsy., [Interpretation] Pexidartinib is the first systemic therapy to show a robust tumour response in TGCT with improved patient symptoms and functional outcomes; mixed or cholestatic hepatotoxicity is an identified risk. Pexidartinib could be considered as a potential treatment for TGCT associated with severe morbidity or functional limitations in cases not amenable to improvement with surgery.

Published
2019

234. Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.

Author

Mweempwa, Angela, Xu, Huiling, Vissers, Joseph H. A., Tothill, Richard W., Pattison, Andrew D., Fellowes, Andrew P., Thomas, David M., Richardson, Gary, Hicks, Rodney J., Grimmond, Sean M., Fox, Stephen B., Luen, Stephen J., Desai, Jayesh, and Solomon, Benjamin J.

Subjects
THYROID cancer, PHEOCHROMOCYTOMA, FIBROBLAST growth factor receptors
Abstract

Pralsetinib (BLU-667) is another highly potent and selective RET inhibitor investigated in the phase I-II ARROW study that subsequently led to its US Food and Drug Administration approval for I RET i fusion-positive lung cancer and I RET i -altered thyroid cancers.[12] Here, we describe a patient with metastatic nonhereditary pheochromocytoma harboring a novel I RET-SEPTIN9 i fusion who demonstrated a rapid response to RET-directed therapy. In conclusion, our case report describes the identification of a novel I RET i I SEPTIN9 i fusion in metastatic pheochromocytoma and effective therapy with the selective RET tyrosine kinase inhibitor selpercatinib, highlighting the need to carry out genomic sequencing in patients with malignant pheochromocytoma. Selpercatinib is the first RET-specific tyrosine kinase inhibitor that has been proven to be active in thyroid cancer and NSCLC harboring I RET i alterations.[10],[11] The clinical response to selpercatinib in our case is attributed to the I RET i I SEPTIN9 i fusion. [Extracted from the article]

Published
2021
Full Text
View/download PDF

235. Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology.

Author

Lin, Frank P., Thavaneswaran, Subotheni, Grady, John P., Ballinger, Mandy, Kansara, Maya, Oakes, Samantha R., Desai, Jayesh, Lee, Chee Khoon, Simes, John, and Thomas, David M.

Subjects
CANCER treatment, CANCER genetics, CANCER diagnosis, COMPUTER algorithms, CLINICAL trials
Abstract

While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide clinical management based on molecular biomarkers. To this end, we have structured a compendium of approved and experimental therapies with associated biomarkers following a survey of drug regulatory databases, existing knowledge bases, and published literature. Each biomarker-disease-therapy triplet was categorised using a tiering system reflective of key therapeutic considerations: approved and reimbursed therapies with respect to a jurisdiction (Tier 1), evidence of efficacy or approval in another jurisdiction (Tier 2), evidence of antitumour activity (Tier 3), and plausible biological rationale (Tier 4). Two resistance categories were defined: lack of efficacy (Tier R1) or antitumor activity (Tier R2). Based on this framework, we curated a digital resource focused on drugs relevant in the Australian healthcare system (TOPOGRAPH: Therapy Oriented Precision Oncology Guidelines for Recommending Anticancer Pharmaceuticals). As of November 2020, TOPOGRAPH comprised 2810 biomarker-disease-therapy triplets in 989 expert-appraised entries, including 373 therapies, 199 biomarkers, and 106 cancer types. In the 345 therapies catalogued, 84 (24%) and 65 (19%) were designated Tiers 1 and 2, respectively, while 271 (79%) therapies were supported by preclinical studies, early clinical trials, retrospective studies, or case series (Tiers 3 and 4). A companion algorithm was also developed to support rational, context-appropriate treatment selection informed by molecular biomarkers. This framework can be readily adapted to build similar resources in other jurisdictions to support therapeutic decision-making. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

236. A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours.

Author

Sarkar, Sunit, Tran, Ben, Horvath, Lisa, Lam, Michael, Savas, Peter, Grimison, Peter, Whittle, James R., Kuo, James C., Signal, Nicole, Edmonds, David, Hogg, Philip, Rischin, Danny, Desai, Jayesh, and Hamilton, Anne

Subjects
INTRAVENOUS therapy, TUMORS, PHARMACOKINETICS, RAPAMYCIN
Abstract

Purpose: This phase I study was conducted to evaluate the safety and Maximum Tolerated Dose of PENAO (4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid), a second-generation organic arsenical with anti-mitochondrial activity, when given as a continuous intravenous infusion (CIVI), in patients with advanced solid tumours. Methods: Eligibility criteria for this trial included age ≥ 18 years, advanced solid tumour, ECOG Performance Status ≤ 1 and adequate organ function. PENAO was administered by CIVI, with dose levels initially increased by infusion duration in a 21-day cycle at a fixed daily dose and then increased daily dose. Standard dose-limiting toxicity (DLT) definitions were used in a "3 + 3" design. Patients had regular monitoring of toxicity and efficacy. Pharmacokinetic assays of serum and urine As were performed. Results: Twenty-six patients were treated across 8 dose levels. The only dose-limiting toxicity (DLT) observed was fatigue, that occurred in one patient treated at the highest dose level of 9 mg/m2/day. No significant organ toxicity or objective responses were observed, although there were two patients with stable disease lasting up to 7 months. Pharmacokinetic analysis unexpectedly indicated a half-life of 9–19 days, invalidating the CIVI dosing resulting in discontinuation of the study before the RP2D was defined. Conclusions: PENAO was administered by CIVI at dose levels up to 9 mg/m2/day with only one DLT noted. Pharmacokinetic studies invalidated the rationale for continuous dosing and led to discontinuation of the trial without defining a RP2D. Future clinical development of PENAO will use intermittent dosing schedule, alone and in combination with rapamycin. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

237. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Author

Canon, Jude, primary, Rex, Karen, additional, Saiki, Anne Y., additional, Mohr, Christopher, additional, Cooke, Keegan, additional, Bagal, Dhanashri, additional, Gaida, Kevin, additional, Holt, Tyler, additional, Knutson, Charles G., additional, Koppada, Neelima, additional, Lanman, Brian A., additional, Werner, Jonathan, additional, Rapaport, Aaron S., additional, San Miguel, Tisha, additional, Ortiz, Roberto, additional, Osgood, Tao, additional, Sun, Ji-Rong, additional, Zhu, Xiaochun, additional, McCarter, John D., additional, Volak, Laurie P., additional, Houk, Brett E., additional, Fakih, Marwan G., additional, O’Neil, Bert H., additional, Price, Timothy J., additional, Falchook, Gerald S., additional, Desai, Jayesh, additional, Kuo, James, additional, Govindan, Ramaswamy, additional, Hong, David S., additional, Ouyang, Wenjun, additional, Henary, Haby, additional, Arvedson, Tara, additional, Cee, Victor J., additional, and Lipford, J. Russell, additional

Published
2019
Full Text
View/download PDF

238. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Author

Kopetz, Scott, primary, Grothey, Axel, additional, Yaeger, Rona, additional, Van Cutsem, Eric, additional, Desai, Jayesh, additional, Yoshino, Takayuki, additional, Wasan, Harpreet, additional, Ciardiello, Fortunato, additional, Loupakis, Fotios, additional, Hong, Yong Sang, additional, Steeghs, Neeltje, additional, Guren, Tormod K., additional, Arkenau, Hendrik-Tobias, additional, Garcia-Alfonso, Pilar, additional, Pfeiffer, Per, additional, Orlov, Sergey, additional, Lonardi, Sara, additional, Elez, Elena, additional, Kim, Tae-Won, additional, Schellens, Jan H.M., additional, Guo, Christina, additional, Krishnan, Asha, additional, Dekervel, Jeroen, additional, Morris, Van, additional, Calvo Ferrandiz, Aitana, additional, Tarpgaard, L.S., additional, Braun, Michael, additional, Gollerkeri, Ashwin, additional, Keir, Christopher, additional, Maharry, Kati, additional, Pickard, Michael, additional, Christy-Bittel, Janna, additional, Anderson, Lisa, additional, Sandor, Victor, additional, and Tabernero, Josep, additional

Published
2019
Full Text
View/download PDF

239. Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index

Author

Day, Daphne, primary, Guo, Christina, primary, Kanjanapan, Yada, primary, Tran, Ben, primary, Spreafico, Anna, primary, Joshua, Anthony M, primary, Wang, Lisa, primary, Abdul Razak, Albiruni R, primary, Leighl, Natasha B, primary, Hansen, Aaron R, primary, Butler, Marcus O, primary, Siu, Lillian L, primary, Desai, Jayesh, primary, and Bedard, Philippe L, primary

Published
2019
Full Text
View/download PDF

240. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

Author

Tap, William D, primary, Gelderblom, Hans, additional, Palmerini, Emanuela, additional, Desai, Jayesh, additional, Bauer, Sebastian, additional, Blay, Jean-Yves, additional, Alcindor, Thierry, additional, Ganjoo, Kristen, additional, Martín-Broto, Javier, additional, Ryan, Christopher W, additional, Thomas, David M, additional, Peterfy, Charles, additional, Healey, John H, additional, van de Sande, Michiel, additional, Gelhorn, Heather L, additional, Shuster, Dale E, additional, Wang, Qiang, additional, Yver, Antoine, additional, Hsu, Henry H, additional, Lin, Paul S, additional, Tong-Starksen, Sandra, additional, Stacchiotti, Silvia, additional, and Wagner, Andrew J, additional

Published
2019
Full Text
View/download PDF

241. Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study

Author

Desai, Jayesh, primary, Markman, Benjamin, additional, Friedlander, Michael, additional, Gan, Hui, additional, Horvath, Lisa, additional, Townsend, Amanda, additional, Millward, Michael, additional, Jameson, Michael, additional, Yen, Chia-Jui, additional, Hou, Ming-Mo, additional, Hou, Jeannie, additional, Wu, John, additional, Liang, Liang, additional, and Deva, Sanjeev, additional

Published
2019
Full Text
View/download PDF

244. Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.

Author

Gelderblom, Hans, primary, Tap, William D., additional, Palmerini, Emanuela, additional, Stacchiotti, Silvia, additional, Wainberg, Zev A., additional, Desai, Jayesh, additional, Healey, John H., additional, van de Sande, Michiel, additional, Bernthal, Nicholas M., additional, Peterfy, Charles, additional, Shuster, Dale Edward, additional, Wang, Qiang, additional, Hsu, Henry, additional, and Wagner, Andrew J., additional

Published
2019
Full Text
View/download PDF

245. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Author

Fakih, Marwan, primary, O'Neil, Bert, additional, Price, Timothy Jay, additional, Falchook, Gerald Steven, additional, Desai, Jayesh, additional, Kuo, James, additional, Govindan, Ramaswamy, additional, Rasmussen, Erik, additional, Morrow, Phuong Khanh H., additional, Ngang, Jude, additional, Henary, Haby A., additional, and Hong, David S., additional

Published
2019
Full Text
View/download PDF

246. Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.

Author

Tap, William D., primary, Speck, Rebecca M, additional, Ye, Xin, additional, Palmerini, Emanuela, additional, Stacchiotti, Silvia, additional, Desai, Jayesh, additional, Wagner, Andrew J., additional, Alcindor, Thierry, additional, Ganjoo, Kristen N., additional, Martin Broto, Javier, additional, Wang, Qiang, additional, Shuster, Dale Edward, additional, Gelhorn, Heather, additional, and Gelderblom, Hans, additional

Published
2019
Full Text
View/download PDF

247. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion

Author

McEvoy, Christopher R., primary, Xu, Huiling, additional, Smith, Kortnye, additional, Etemadmoghadam, Dariush, additional, San Leong, Huei, additional, Choong, David Y., additional, Byrne, David J., additional, Iravani, Amir, additional, Beck, Sophie, additional, Mileshkin, Linda, additional, Tothill, Richard W., additional, Bowtell, David D., additional, Bates, Bindi M., additional, Nastevski, Violeta, additional, Browning, Judy, additional, Bell, Anthony H., additional, Khoo, Chloe, additional, Desai, Jayesh, additional, Fellowes, Andrew P., additional, Fox, Stephen B., additional, and Prall, Owen W.J., additional

Published
2019
Full Text
View/download PDF

248. PD47-01 BMS-986205, AN INDOLEAMINE 2,3-DIOXYGENASE 1 INHIBITOR, PLUS NIVOLUMAB: UPDATED SAFETY ACROSS ALL TUMOR COHORTS AND EFFICACY IN ADVANCED BLADDER CANCER

Author

Luke*, Jason, primary, Tabernero, Josep, additional, Gelmon, Karen, additional, Varga, Andrea, additional, Moreno, Victor, additional, Desai, Jayesh, additional, Markman, Ben, additional, Gomez-Roca, Carlos, additional, De Braud, Filippo, additional, Patel, Sandip, additional, Carlino, Matteo, additional, Siu, Lillian, additional, Curigliano, Giuseppe, additional, Liu, Zhaohui, additional, Ishii, Yuko, additional, Wind-Rotolo, Megan, additional, Basciano, Paul, additional, Azrilevich, Alex, additional, and Joshua, Anthony, additional

Published
2019
Full Text
View/download PDF

249. BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).

Author

Luke, Jason J., primary, Tabernero, Josep, additional, Joshua, Anthony, additional, Desai, Jayesh, additional, Varga, Andrea I., additional, Moreno, Victor, additional, Gomez-Roca, Carlos A., additional, Markman, Ben, additional, De Braud, Filippo G., additional, Patel, Sandip Pravin, additional, Carlino, Matteo S., additional, Siu, Lillian L., additional, Curigliano, Giuseppe, additional, Liu, Zhaohui, additional, Ishii, Yuko, additional, Wind-Rotolo, Megan, additional, Basciano, Paul Andrew, additional, Azrilevich, Alex, additional, and Gelmon, Karen A., additional

Published
2019
Full Text
View/download PDF

250. A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer

Author

Lok, Sheau W., primary, Whittle, James R., additional, Vaillant, François, additional, Teh, Charis E., additional, Lo, Louisa L., additional, Policheni, Antonia N., additional, Bergin, Alice R.T., additional, Desai, Jayesh, additional, Ftouni, Sarah, additional, Gandolfo, Luke C., additional, Liew, Danny, additional, Liu, He K., additional, Mann, G. Bruce, additional, Moodie, Kate, additional, Murugasu, Anand, additional, Pal, Bhupinder, additional, Roberts, Andrew W., additional, Rosenthal, Mark A., additional, Shackleton, Kylie, additional, Silva, Maria João, additional, Siow, Zhen R., additional, Smyth, Gordon K., additional, Taylor, Leanne, additional, Travers, Avraham, additional, Yeo, Belinda, additional, Yeung, Miriam M., additional, Bujak, Andjelija Zivanovic, additional, Dawson, Sarah-Jane, additional, Gray, Daniel H.D., additional, Visvader, Jane E., additional, and Lindeman, Geoffrey J., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results